Anti-SELP (Crizanlizumab), Humanized Antibody

Anti-SELP (Crizanlizumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a humanized IgG2, kappa monoclonal antibody that selectively targets P-selectin (SELP). P-selectin is a glycoprotein found on the surface of endothelial cells. It belongs to the family of Selectins and functions as a cell adhesion molecule (CAM). Upon binding to its ligand P-selectin glycoprotein ligand-1 (PSGL-1, SELPLG), SELP controls the flow of white blood cells and how they adhere to the walls of blood vessels during inflammatory and tissue repair conditions. In sickle cell anemia, SELP increases the adhesion of sickle cell red blood cells to blood vessels, thereby restricting blood flow and causing inflammation and pain crises. The monoclonal antibody binds to SELP and prevents its interaction with the ligand and thus restores the normal flow of the blood. The original monoclonal antibody is FDA approved to treat patients with sickle cell disease and sickle cell-associated vaso-occlusive crises

Immunogen Sequence:Human P-Selectin

Target Alternative Name:CD62, GRMP, PSEL, CD62P, GMP140, LECAM3, PADGEM, SELP

Species Reactivities:Human

Tag Line:The biosimilar is a humanized monoclonal antibody that targets P-Selectin (SELP) and inhibits its interaction with P-selectin glycoprotein ligand-1 (PSGL-1) on neutrophils and monocytes, thereby maintaining the normal flow of blood. The original monoclonal antibody is approved by the FDA to treat sickle cell anemia and sickle cell-associated vaso-occlusive crises

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.